Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib, according to a presentation at the International Association for the Study of Lung Cancer World Conference on Lung Cancer Virtual Presidential Symposium.